StemCell Therapy

stem cell therapy Egypt
/ 01002527255 : http://www.facebook.com/espcr.

By:

Originally posted here:
stem cell therapy Egypt - Video

treatment available for autism spectrum disorder
After stem cell therapy treatment available for autism spectrum disorder parents of the child from London United Kingdom testifying most of the amazing improvements they saw after stem cell...

By: Neurogen Brain and Spine Institute

The rest is here:
treatment available for autism spectrum disorder - Video

PUBLIC RELEASE DATE:

19-Jun-2014

Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (June 19, 2014) Researchers in Taiwan have found that peripheral blood stem cells "mobilized" by a special preparation of granulocyte colony-stimulating factor (G-CSF) prior to their injection into rats modeling osteoarthritis (OA), stimulated the bone marrow to produce stem cells, leading to the inhibition of OA progression. The finding, they said, may lead to a more effective therapy for OA, a common joint disease that affects 10 percent of Americans over the age of 60.

The study will be published in a future issue of Cell Transplantation and is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1109Deng.

"Currently, OA treatment involves the use of anti-inflammatory drugs, analgesics, lubricating supplements, or surgery," said study lead author Dr. Shih-Chieh Hung of the Department of Medical Research and Education at the Taipei Veterans general Hospital in Taiwan. "Recently, hematopoietic (blood) stem cells derived from bone marrow have emerged as a potential treatment for OA. We hypothesized that G-CSF-mobilized peripheral blood stem cells (gm-PBSCs) contain a population of primitive stem cells that have the capacity for mobility once released from stem cell niches."

While the beneficial effects of G-CSF-mobilized peripheral blood stem cells have been documented when used for treating the negative effects of chemotherapy and radiation, as well as peripheral arterial diseases, this is the first study to investigate the use of gm-PBSCs to treat skeletal diseases, such as OA.

"We demonstrated that PBSCs, mobilized by G-CSF and infused for five days in rats modelling OA, provided a number of beneficial results, including increasing cluster of differentiation 34 positive (CD34+) cell percentages up to 55 fold," reported the authors. "Further, we demonstrated that the progression of OA was inhibited by the gm-PBSCs."

The researchers noted that the use of G-CSF administration in humans to treat other diseases and conditions has been found to be "safe and effective," despite known side effects such as bone pain, headache, fatigue, and nausea which, they added, are generally "transient, self-limiting and without long-term consequences."

"Although potential long-term adverse effects, such as malignancy after G-CSF administration have been reported, the frequency is low and the relationship between major adverse effects and G-CSF administration is not clear," said Dr. Hung.

Here is the original post:
Stem cell mobilization therapy may effectively treat osteoarthritis

Dr. Omar Gonzalez presents Best Stem Cell Therapy in Mexico: Integrative Medicine Clinic
http://www.placidway.com/profile/705/ - Watch this Video as Dr.Omar Gonzalez, MD, specialist in Stem Cell Therapy, Integrative Medicine and Chronic Diseases, presents his new clinic located...

By: placidways

View post:
Dr. Omar Gonzalez presents Best Stem Cell Therapy in Mexico: Integrative Medicine Clinic - Video

DUBLIN, June 19, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/v969qd/cell_separation) has announced the addition of the "Cell Separation Technologies Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

This report consists of the market analysis for the various technologies used in the cell separation market. Increasing cell therapy oriented research and development globally is driving the cell separation technologies market towards significant growth. The stakeholders for this report include providers and manufacturers of cell separation technology instruments.

The cell separation technologies market is segmented on the basis of technologies that are available in the market and application areas of cell separation technologies. The various technology segments covered in this report are gradient centrifugation and separation based on surface markers. Separation based on surface markers technology include two different techniques namely, magnetic activated cell sorting (MACS) and fluorescence activated cell sorting (FACS).

The application areas of cell separation technologies comprise stem cell research, immunology, neuroscience research and cancer research. Revenue forecast and market analysis for each segment has been given in this study for the period of 2011 to 2019 in terms of USD million in addition to the compound annual growth rate (CAGR %) for each segment of technology and application. The CAGR is provided for forecast period of 2013 to 2019 and 2012 have been considered as base in year for market size estimation.

Geographically, global cell separation technologies market has been segmented into four areas namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). This report also provides the present and future market estimation in terms of USD million for the period 2011 to 2019, in addition to compound annual growth rate (CAGR %) for each geographic area. Further to market size estimation, this report provides recommendations and highlights of the market that should be useful for current and new market players to grow and sustain in the global cell separation technologies market.

Market trends and dynamics such as restraints, opportunities and growth drivers that have impact on present and future position of this market are demonstrated in the market overview chapter of this study. In addition, the market overview chapter also consists of Porter's five forces analysis and market attractiveness by geography to give detailed analysis of the entire competitive status of the global cell separation technologies market.

Key information about the top market players operating in the global cell separation technologies market is given in the company profiles section of this report. Some of the key players profiled in this report include BD Bioscience, EMD Millipore, Mitenyi Biotec GmbH, and STEMCELL Technologies, Terumo BCT, pluriSelect GmbH, and Life Technologies (Thermo Fisher Scientific, Inc.).

Key Topics Covered:

Chapter 1 Introduction

Continued here:
Cell Separation Technologies Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

PUBLIC RELEASE DATE:

9-Jun-2014

Contact: Kimberly Brown kbrown@snmmi.org 703-652-6773 Society of Nuclear Medicine

St. Louis, Mo. (June 9, 2014) Researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting revealed how a protein encourages the production of stem cells that regenerate damaged tissues of the heart following an acute attack (myocardial infarction). They further assert that it has a better chance of working if provided early in treatment. This was confirmed by molecular imaging, which captured patients' improved heart health after therapy.

If given after a heart attack, granulocyte colony-stimulating factor (G-CSF) mobilizes bone marrow stem cells that turn down the collateral damage of cell death that occurs after acute myocardial infarction. Other research has shown G-CSF having a beneficial impact on left ventricle ejection fraction, a measurement of how powerfully the heart is pumping oxygenated blood back into the aorta and the rest of the body with each beat. The objective of this study was to find out how beneficial the stem cellstimulating therapy would be if administered early during standard treatment. Early prescription of G-CSF happens to strengthen its effect immediately and after follow up.

"Previous studies have shown that giving G-CSF to unselected heart attack patients failed to satisfactorily improve their condition, but G-CSF may potentially be beneficial if given earlier than 37 hours following myocardial infarction and coronary intervention," remarked Takuji Toyama, MD, the study's principal researcher from the division of cardiology at Gunma Prefectural Cardiovascular Center in Maebashi, Japan. "This study shows that the first intravenous drip infusion of G-CSF during treatment just after hospitalization was able to rescue our patients. I am confident that with additional data from a forthcoming clinical trial, this protocol can be adopted as a standard of practice."

For this study, 40 consecutive patients with acute myocardial infarction were given either G-CSF therapy or saline intravenously for a total of five days beginning during a selected minimally invasive treatment, otherwise known as percutaneous cardiac intervention. Results of one year's worth of SPECT stress tests nailed how earlier start of G-CSF therapy in heart attack patients improves blood flow, access to essential energy and overall cardiac function.

Coronary heart disease caused one out of every six fatalities in the U.S. in 2010, according to 2014 statistics from the American Heart Association. An estimated 620,000 Americans suffered a first heart attack, and 295,000 had a recurrent episode. Collectively, heart attacks occur about once every 34 seconds. Coronary events cause about 379,559 deaths each year.

###

Scientific Paper 239: Takuji Toyama, Hiroshi Hoshizaki, Hakuken Kan, Ren Kawaguchi, Hitoshi Adachi, Shigeru Ohsima, Division of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Japan; Masahiko Kurabayashi, Department of Cardiovascular Medicine, Gunma University School of Medicine, Maebashi, Japan, "Is the granulocyte colony-stimulating factor therapy in the earliest phase effective to rescue patients with acute myocardial infarction?" SNMMI's 61th Annual Meeting, June 7, 2014, St. Louis, Missouri.

See the rest here:
Stem cell-stimulating therapy saves heart attack patients

Patient Testimonial: Stem cell therapy for COPD Treatment in SERBIA
http://www.placidway.com/profile/1617/ - Marko was treated for COPD with Stem Cell Therapy in Swiss Medica #39;s Serbian Clinic. How the treatment effectiveness ...

By: placidways

Read the original:
Patient Testimonial: Stem cell therapy for COPD Treatment in SERBIA - Video

Successful Fetal Stem Cell Therapy in Kyiv, Ukraine at EmCell via PlacidWay
Watch Daniel #39;s testimonial after undergoing successful Fetal Stem Cell Therapy at EmCell in Kyiv, Ukraine.

By: placidways

Link:
Successful Fetal Stem Cell Therapy in Kyiv, Ukraine at EmCell via PlacidWay - Video

La Jolla, CA (PRWEB) June 17, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases, today announced their newest clinical study for Multiple Sclerosis. StemGenex believes that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.

This clinical study is bringing to the field a new, unique type of stem cell therapy that has the possibility of being more effective than other stem cell treatments currently available. Patients who receive stem cell treatment through StemGenex for Multiple Sclerosis will receive StemGenex multiple administration protocol. This consists of four targeted administration methods of the stem cells to deliver the necessary amount of stem cells past the blood brain barrier.

Principal Investigator Dr. Jeremiah McDole, Ph.D. stated, "Currently available drugs for multiple sclerosis do not halt disease progression or aid in the repair of established damage. We strive to provide regenerative medicine applications that address this critical, underlying issue. While patients experience positive clinical outcomes as a result of stem cell treatment, large, rigorously performed studies are desired in order to guide our best efforts for future development. The study we are conducting is designed to provide us with this essential data."

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval. According to StemGenex Director of Patient Advocacy, Joe Perricone, It is important patients have access to top-tier stem cell treatment. By providing access to registered clinical studies through The National Institutes of Health, we are providing patients with the ability to choose a stem cell treatment center with the highest standard of care.

Rita Alexander, founder and president of StemGenex, stated, This is the first of many stem cell clinical studies to come and a positive step for the more than 2 million people around the world suffering with Multiple Sclerosis. The average lifetime cost of current standard of care treatment per MS patient is $1.2 million. The human cost of the disease including pain and suffering endured by MS patients, the profound impact on families and the loss of their ability to contribute to society is without question immeasurable. Dr. McDoles research background in neuroimmunology is certainly an asset in our effort to change the course of neurological diseases.

Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Multiple Sclerosis and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Parkinsons and Alzheimers disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact(at)stemgenex(dot)com

See the original post:
StemGenex Announces New Stem Cell Clinical Study for Multiple Sclerosis

Tampa, FL (PRWEB) June 19, 2014

Located in Tampa, FL, Lung Institute was instrumental in allowing Robert Ware get his life back. Three months ago, Robert decided to take his health into his own hands and move ahead with stem cell treatment. Hundreds of people with lung disease have been treated with the companys innovative use of stem cells from the patients own body.

Stem cell therapy is a viable option for many people with lung disease, said Dr. Burton Feinerman, Medical Director of the Lung Institute. Our patients are breathing easier, walking further, and depending less on supplemental oxygen.

For Robert, 71, chronic obstructive pulmonary disease (COPD) was taking over his life. Over the past decade, this progressive lung disease diminished his quality of life and forced him away from the activities he used to love. Robert was unable to be outdoors, attend live music shows in the town squares and work on his yard and landscaping. A few months ago, Robert had a health scare that he thought was a heart attack. He was actually experiencing lung spasms and not receiving enough oxygen, often referred to as a COPD exacerbation.

COPD is not only the third leading cause of death in the United States, but is responsible for severely limiting sufferers quality of life. People with COPD often cant even walk to their mailbox without debilitating shortness of breath. For people without COPD, it is akin to breathing through a small straw while carrying out normal activities.

In Roberts case, his exacerbation caused him to look for alternatives to the traditional medications he had been taking. Robert and his wife decided stem cell therapy at the Lung Institute was the best option for him. Robert received autologous stem cell therapy, meaning stem cells from his own body were used to help cue natural healing processes for damaged lung tissue. After the minimally invasive, outpatient procedure, Robert returned home and was able to regain a substantial amount of his quality of life.

Before treatment, I was pretty much on oxygen all the time, said Robert. I couldnt do much without my oxygen. Today, Im doing just about anything I want to do.

Now, Robert no longer needs to pay someone to take care of his lawn. Robert is able to be outdoors, mow the grass, work around the house and go out with friends.

People are just amazed how well Im doing. Im probably 75% to what I was originally, 10 years ago, added Robert. I started getting better fast and my friends couldnt believe it. They were shocked. It was kind of funfeeling good, rather than being sick.

About Lung Institute At Lung Institute (LI), we are changing the lives of hundreds of people across the nation through the innovative technology of regenerative medicine. We are committed to providing patients a more effective way to address pulmonary conditions and improve quality of life. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive stem cell therapies. With over a century of combined medical experience, our doctors have established a patient experience designed with the highest concern for patient safety and quality of care. For more information, visit our website at LungInstitute.com, like us on Facebook, follow us on Twitter or call us today at 1-855-469-5864.

Here is the original post:
Lung Institute Instrumental in Allowing Robert Ware to Get His Life Back

Contact Information

Available for logged-in reporters only

Newswise LOS ANGELES (June 17, 2014) Stem cell therapy for cardiovascular disease isnt a medical pipe dream its a reality today, although patients need to better understand the complex science behind these experimental treatments, according to the chief of Cardiology for the Cedars-Sinai Heart Institute.

In a 17-minute TEDxGrandForks talk now available on YouTube.com, Timothy D. Henry, MD, known for his innovative work in developing stem cell treatments for advanced heart disease patients, said he understands why so many are confused about the latest scientific findings.

Most people today get our information from sound bites, and the issues surrounding stem cells are too complex to be fully explained in a single catchy phrase, Henry said, adding, We have far too much controversy about stem cells and far too much hype.

Stem cell science has become a political dividing line with many opposing research into stem cells derived from human embryos, Henry said. However, he said, todays leading-edge clinical research focuses on stem cells derived from adults that can be scientifically programmed to become a specialized cell, such as a heart cell or a brain cell, thereby avoiding the ethical questions involved in embryonic research.

Very few of the cells we give actually become muscle or actually become blood vessels, Henry said. What they do is increase growth factors and encourage natural cells in the body to generate new, healthy tissue.

The Cedars-Sinai Heart Institute, directed by Eduardo Marbn, MD, PhD, is a world leader in studying the use of stem cells to regenerate heart muscle in patients who have had heart attacks. In 2009, Cedars-Sinai physicians conducted the first infusion of stem cells into heart attack patients, using stem cells grown from the patients own heart tissue. The resulting study, published in February 2012 in The Lancet, showed that patients who underwent the stem cell procedure experienced a significant reduction in the size of the scar left behind by a heart attack. Patients also experienced a sizable increase in healthy heart muscle following the experimental stem cell treatments.

Currently, Henry is co-directing a new stem cell study with Raj Makkar, MD, director of Interventional Cardiology. The national trial, called ALLSTAR, uses heart cells from unrelated donors in an effort to reverse lasting tissue damage after a heart attack.

During his talk, Henry also expressed concern for patients who might be taken advantage of by unscrupulous clinics outside of the United States that offer stem cell cures for everything from neurological diseases to baldness. Patients also need to understand that stem cell science has a long way to go before regenerative medicine treatments are widely available.

Read more here:
Stem Cell Expert Explains How Experimental Regenerative Medicine Therapies Can Regrow Damaged Heart Muscle

Obesity Weight (Stem Cell Therapy)
The subject matter of this video Obesity Weight.

By: Mohammad Sadique

Read the original:
Obesity & Weight (Stem Cell Therapy) - Video

Stem Cell Therapy for Anti-Aging Treatment, How it works?
http://www.placidway.com/package/1023/Affordable-Therapeutic-Treatment-In-Lugano%2C-Switzerland - Antiaging treatments have been and will continue to be a hot topic among men and women of all...

By: placidways

See the article here:
Stem Cell Therapy for Anti-Aging Treatment, How it works? - Video

Beverly HIlls, California (PRWEB) June 09, 2014

The top stem cell doctor in Beverly Hills and Los Angeles at Beverly Hills Orthopedic Institute are now offering stem cell procedures for hip arthritis. The stem cell therapy typically provides pain relief along with being able to delay or avoid the need for joint replacement. Call (310) 438-5343 for more information and scheduling.

Dr. Raj, Medical Director at Beverly Hills Orthopedic Institute, is a Double Board Certified orthopedic doctor who has been a pioneer in stem cell therapy for musculoskeletal conditions. Several types of stem cell procedures are offered including bone marrow derived along with amniotic derived procedures.

For the bone marrow stem cell procedures, a short outpatient procedure involves harvesting bone marrow from the patient's iliac crest. The stem cells are immediately processed to concentrate the growth factors and cells, and then they are injected into the hip for pain relief and tissue regeneration.

For the amniotic derived procedures, the fluid is obtained from consenting donors after a scheduled c-section procedure. There is no fetal tissue utilized, and the fluid is processed at an FDA regulated laboratory. An immense amount of stem cells, growth factors and hyaluronic acid are present in the amniotic material.

Dr. Raj has performed a significant amount of stem cell procedures utilizing both methods for hip arthritis, with the results being stellar to date. Being Double Board Certified and a sports medicine expert, Dr. Raj also offers stem cell procedures for sports injuries such as tendonitis and ligament injuries. This includes rotator cuff tendonitis, knee injuries, elbow tendonitis and more.

Beverly Hills Orthopedic Institute is the premier stem cell clinic in Los Angeles and Beverly Hills. Dr. Raj is an ABC News Medical Correspondent and a WebMD Medical Expert. For information on how stem cell therapy can help, call Beverly Hills Orthopedic Institute at (310) 438-5343.

See the article here:
Beverly Hills Orthopedic Institute Now Offering Revolutionary Stem Cell Procedures for Hip Arthritis to Avoid Joint ...

An Okotoks boy may not understand his community is helping to give him a better life this weekend, but there is a good chance he will be smiling anyway.

At four years old, Ryker Menzies communicates through a series of sounds, suffers from frequent muscle spasms, is in a wheelchair because hes unable to walk or sit on his own and is constantly on painkillers.

This has been Rykers reality since infancy due to a severe case of cerebral palsy, and his parents Tiffany Boyd and Jamie Menzies are hopeful stem cell therapy treatment in Panama City will improve his muscle movement, vision and speech.

Unfortunately, they havent been able to afford the procedure living on one income while Boyd cares for Ryker.

To help pay for the $15,600 treatment, the couple is organizing a mini-market at the Foothills Centennial Centre on June 14 from 11 a.m. to 4 p.m. and inviting the community to check out an abundance of second-hand items and products from home-based and privately-owned businesses for an entry fee of $2.

Money will also be raised through a food vendor, numerous raffle tickets for prizes including vacations and toys, and items donated by residents. Okotoks singer Emily Gryba will perform at the event.

Ive been getting a lot of calls from people donating stuff to the market to sell there, as well as a few online donations, said Boyd. We will just set up about five tables and have family run them. The proceeds will go to Ryker.

Boyd said she is ecstatic at the amount of community support for Rykers stem cell treatment. An online fund she established called Raise for Rykstar collected $1,300, with another $2,000 donated by family, friends and community members.

The feedback has been fantastic, she said. Were already at $3,500.

As the family gets closer to reaching their financial goal, Boyd is eager to book an appointment to give Ryker the best life possible. She said she was told they will have an appointment within a month or two of making the call.

View original post here:
Boy getting a chance for a better life

Stem Cell therapy - pioneering treatment for muscular dystrophy
Neuromuscular specialist Professor Jenny Morgan presents on the new advances in stem cell research for muscular dystrophy, at Muscular Dystrophy Campaign eve...

By: Muscular Dystrophy Campaign

Read more here:
Stem Cell therapy - pioneering treatment for muscular dystrophy - Video

torn rotator cuff/shoulder arthritis one year after stem cell therapy by Dr Harry Adelson
Richard discusses his outcome from bone marrow/adipose derived stem cells by Dr Harry Adelson for his torn rotator cuff and arthritic shoulder http://www.docereclinics.com.

By: Harry Adelson, N.D.

Continued here:
torn rotator cuff/shoulder arthritis one year after stem cell therapy by Dr Harry Adelson - Video

Stem Cell Therapy Market by Treatment Mode Therapeutic Applications - 2020
[196 Slides Report] Stem Cell Therapy Market report categories the Global market by Therapeutic Applications (CNS, CVS, Musculoskeletal, Wound Healing, GIT, Eye, Immune System), Treatment...

By: James Evans

View original post here:
Stem Cell Therapy Market by Treatment Mode & Therapeutic Applications - 2020 - Video

New York, NY (PRWEB) June 04, 2014

The Animal Medical Center of New York is offering stem cell therapy provided through Vet-Stem and long-term management in a clinical trial for qualifying cats with chronic kidney disease (CKD). The ultimate goal of this study is to investigate the use of stem cells (obtained from the patients own fat) in aiding the enhancement of renal (kidney) function by their regenerative capabilities, with the goal of improving survival in cats with CKD.

Currently there are no therapeutic options for cats with CKD other than renal transplantation, which is not typically an option for most owners. Most efforts aim at improving uremic signs with food, dietary supplements, and antacids, but there are no current methods for improving function of the kidney directly. CKD is the leading cause of death in older cats, and 35% of cats will develop CKD at some point.

Since renal failure is so common in cats and renal cell death is the ultimate result, improving the health and environment of the cells that remain could improve the overall function of the kidneys and ultimately improve the survival times and quality of life in patients. The aim is to use the cats own adipose (fat) derived stem cells to improve renal function directly, as stem cells are thought to improve, repair, and aid in the growth of damaged tissue.

The potential health benefits of using stem cells to combat CKD include renal regeneration, anti-fibrotic effects, a decrease in proteinuria (also called urine albumin or an abnormal amount of protein in the urine), and an improvement in the Glomerular Filtration Rate (GFR used to help measure kidney function). AMC is offering free fat collection, isolation of the stem cells from the fat, and intra-arterial injection for qualifying cats, as well as free follow-up for three years. Qualifying cats must be diagnosed with IRIS Stage 3 CKD that have had no other experimental therapies. Potential candidates must undergo a full workup and have no history of urinary tract stone disease or the presence of other concurrent, unrelated disease.

Allyson Berent, DVM, DACVIM and Catherine E. Langston, DVM, DACVIM will be leading the three year study, and invite owners with a cat that has been diagnosed with CKD to call 212.329.8763 for more information on qualifying for the clinic trial. To learn more about the study go to http://www.amcny.org/clinicaltrials. To watch a short special interest film about one cats success go to http://www.vet-stem.com/pr_detail.php?id=49.

The Animal Medical Center in New York City is a federally recognized 501(c)(3) non-profit veterinary center that has been a national leader in animal care since 1910. As an academic veterinary hospital, The AMC promotes the health and well-being of companion animals through advanced treatment, research and education. Stem Cell Therapy through Vet-Stem has been offered at AMC since 2008 to treat pain associated with chronic osteoarthritis. To find out more about AMC and their stem cell therapy services for osteoarthritis go to http://www.amcny.org/surgery/neurosurgery/stem-cell-therapy.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Read more here:
Animal Medical Center of New York Seeks Candidates for Clinical Trial for Cats with Chronic Kidney Disease to Receive ...

stem cell therapy - treatment for mr with delayed milestones by dr alok sharma, mumbai, india
after stem cell therapy treatment for mental retardation with delayed milestones by dr alok sharma, mumbai, india. Stem Cell Therapy done date 18/02/2013 After Stem Cell Therapy OT assessment:...

By: Neurogen Brain and Spine Institute

Read more:
stem cell therapy - treatment for mr with delayed milestones by dr alok sharma, mumbai, india - Video